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Abstract
Molecular Cancer has been launched for one year now. Here, we describe achievements of the past
year and future goals of the journal.
Editorial
It is a time of change [1]. There is no doubt that the uncen-
sored exchange of scientific results hastens progress and
will be the gold standard for any journal [2–7]. BioMed
Central, the publisher of Molecular Cancer, is passionately
committed to maximizing the visibility and impact of
published papers by open-access publishing. In addition,
our online submission and processing system allows that
manuscripts are quickly reviewed, revised, re-reviewed
and published without moving a piece of paper.
Molecular Cancer, an open-access and on-line journal,
publishes cutting-edge papers from all areas of cancer-
related science [5,8]. This journal publishes each article
immediately upon acceptance as a provisional portable
document file (PDF) followed by a fully formatted PDF
and web version. As a fully peer-reviewed journal, Molecu-
lar Cancer publishes selected papers from among the arti-
cles submitted, due to stringent criteria our referees and
editors impose on manuscripts (Figure 1). Acceptance of
papers is based on the originality of the observation or
investigation.
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Table 1: Four most accessed papers of all time published by Molecular Cancer. Data as of July 22, 2003
Article Access Count (all time)
1 Zhang et al. [10] 3182
2 Lynch et al. [13] 2961
3 Delsite et al. [14] 2742
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Manuscripts submitted for publication must meet the
journal's criteria for acceptance. Each manuscript must
have a foundation of well-developed, solid data plus a sig-
nificant advance over existing literature. Pre-submission
inquiries will be screened and authors receive a response
no later than one day after receiving the request. After
passing initial screening, the manuscript will be subjected
to rigorous and anonymous peer-review by three or more
scientists. Associate and deputy Editors serve as core refe-
rees. The authors are informed of the comments made on
their paper without delay. A few examples may illustrate
how quickly papers are reviewed and published. The
paper by Nawaz et al [9] may be one example. Hours after
receiving the paper, we sent it out to three referees outside
the editorial board and revised by the authors. Finally, we
accepted the paper on the following day. This achieve-
ment is due to on-line processing system that the journal
employs. Molecular Cancer published a number of pivotal
research papers in its first year. The readers frequently
accessed number of the published papers. For example,
the paper by Zhang et al [10] has been accessed over 3000
times. This probably would not have been achieved if
access had been restricted by subscription.
Review papers published by Molecular Cancer describe
new developments of interdisciplinary significance and
highlights unresolved questions and future directions; it
provides a critical but balanced view of the field. Reviews
focus on one topical aspect of a field rather than providing
a comprehensive literature survey. They can be controver-
sial, but in this case should indicate opposing viewpoints.
Reviews should not be focused on the author's own work.
The review by Kunz et al [11] tops the list for the most
accessed papers in the last thirty days with more than 400
hits per month. Again, access without any restriction and
limitation maximizes visibility and impact of published
papers. Access rates and numbers of citation will finally
prove the scientific merit of any published paper, no mat-
ter if it is a review, hypothesis or research paper (table 1
and table 2).
During my time as editor of Molecular Cancer, I received
many encouraging e-mails from fellow readers and con-
tributors. Readers appreciate the open-access policy of our
publisher. In addition, it is positively noted that large
amounts of data appear on the journal site [12]. Last but
Table 2: The four most accessed papers from the last month. Data as of July 22, 2003.
Article Access Count (last 30 days)
1 Kunz and Ibrahim [11] 425
2 Narayan et al. [16] 368
3 Wary et al. [17] 357
4 Zhang et al. [10] 332
Paper Statistics 2002/2003 Figure 1
Paper Statistics 2002/2003. Pie chart displaying accept-
ance rate of papers submitted to Molecular Cancer. Data is 
for the first publication year, from June 2002 to July 2003. A 
total of 48 research papers were received, including pre-sub-
mission inquiries, Molecular Cancer rejected 32 (66%), and 
published 16 papers (33%) The median turnaround time of 
publication was one month. Invited papers, e.g. reviews and 
editorials, are not included in this calculation.
Research Paper Statistics 2002/2003
Rejected
2/3
Accepted
1/3Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
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not least, every paper published by Molecular Cancer is
available through PubMed.
Conclusions
Molecular Cancer publishes manuscripts in all areas of can-
cer-related science. Papers are be subjected to fast, fair, rig-
orous and anonymous peer-review. Once, a paper passed
the peer-review process, it appears immediately as just
published manuscript PDF followed by a fully formatted
PDF and web version. All published papers are indexed in
PubMed and archived in PubMed Central.
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